| |MARCH 20269PFIZER TILREKIMIG SHOWS COMPETITIVE RESULTS IN PHASE 2 ECZEMA TRIALROCHE PHARMA INDIA AND PUNJAB LAUNCH NEUROSAKHI TO BOOST MS CAREPfizer has reported encouraging tilrekimig Phase 2 results for adults with moderate to severe atopic dermatitis, showing the investigational drug met its primary endpoint and delivered meaningful improvements in disease severity.The study found a statistically significant increase in patients achieving EASI-75, defined as at least a 75% reduction in the Eczema Area and Severity Index, at Week 16 compared with placebo.The therapy, tilrekimig, is a trispecific antibody designed to block three inflammatory pathways--interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). By targeting these signals, the treatment aims to control the overactive Type 2 immune response that drives chronic inflammatory conditions such as atopic dermatitis, while avoiding effects on healthy cells.In Stage 2 of the Phase 2 trial, which evaluated monthly dosing, the drug showed competitive efficacy. Patients receiving the low dose achieved EASI-75 at a rate of 38.7%, while the middle and high doses reached 51.9% and 49.4%, respectively."The two highest dose levels tested with tilrekimig strongly suggest potentially meaningful improvements to approved standard of care biologics," Pfizer said.Commenting on the tilrekimig Phase 2 results, Mike Vincent, Chief Inflammation & Immunology Officer at Pfizer, said: "We are encouraged by the topline Phase 2 results for tilrekimig, which show that combining the potent inhibition of IL-4/13 and TSLP pathways has the potential to deliver improved efficacy over the standard of care for atopic dermatitis."The treatment was generally well tolerated, with adverse events similar to placebo. Common side effects included infections, skin reactions, and administration site issues. Three serious adverse events were reported but were considered unrelated to treatment. Rates of conjunctivitis were also lower than those typically seen with IL-4 receptor alpha inhibitors.The ongoing Phase 2 study includes four overlapping stages and is also evaluating the therapy in biologic-experienced patients. Researchers are comparing tilrekimig with ompekimig, another trispecific antibody targeting IL-4, IL-13, and IL-33. PORoche Pharma India today launched NeuroSakhi, a first?of?its?kind patient support and awareness initiative with the Government of Punjab.The program aims to strengthen care pathways, increase MS awareness, and support women living with multiple sclerosis in the state. MS is a chronic neurological condition affecting the central nervous system and can cause long-term disability if not diagnosed and treated early.The initiative was formalized through a Memorandum of Understanding (MoU) signed between DMER Punjab and Roche Pharma India at the Punjab Civil Secretariat. Punjab Health Minister Balbir Singh and Principal Secretary­Health Kumar Rahul were present, along with Dr. Hitinder Kaur, Dr. Rupinder Bakshi, and Dr. Dheeraj Khurana of PGIMER Chandigarh.Nearly 2,900 people in Punjab live with MS, which mostly affects women between ages 20 and 40. Despite global awareness, many face delayed diagnosis and fragmented care. NeuroSakhi addresses these gaps by improving awareness, support services, and engagement among healthcare professionals, patients, and caregivers.PGIMER Chandigarh will serve as the central hub, with Government Medical Colleges in Amritsar, Patiala, and Faridkot as regional spokes for coordinated care. The initiative will also improve access to disease?modifying therapies through government formulary inclusion.DMER Punjab will lead implementation, PGIMER Chandigarh will guide clinical efforts, and Roche Pharma India will provide scientific and technical support. The program will run for one year, with potential to expand across India. PO
< Page 8 | Page 10 >